Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Forty-one patients with recurrent primary malignant brain tumors were treated with 2,5-diaziridinyl 3,6-bis (carboethoxyamino), 1,4-benzoquinone (AZQ) at an initial dose of 6–8 mg/m2/ day × 5 days. Courses were repeated monthly upon recovery of myelosuppression. Six of 25 evaluable patients (24%) showed definite tumor regression, and 7 (28%) showed disease stability as determined by monthly CT scans and neurologic examination. For all patients receiving one course of AZQ, the response rate was 16% (6 of 37 patients) and the stable disease rate 19%. The estimated median time to tumor progression with AZQ was 54 weeks for the responding patients and 36 weeks for the stable patients. Toxicity consisted of myelosuppression, primarily thrombocytopenia, which was delayed and cumulative. Other toxicities were uncommon. Further clinical trials in patients with malignant primary brain tumors, including combination studies with other drugs, are indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khan AH and Driscoll JS: Potential central nervous system antitumor agents — aziridinylbenzoquinone. J Med Chem 19:213–317, 1976.

    Google Scholar 

  2. Mellet LB: Physicochemical consideration and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 61:527–531, 1977.

    Google Scholar 

  3. Driscol JS, Dudeck L, Congleton G, Geran RI: Potential CNS antitumor agents VI. J Pharm Sci 68:185–188, 1979.

    Google Scholar 

  4. Chou FL, Khan AH, Dricsol JS: Potential central nervous system antitumor agents — aziridinylbenzoquinone. J Med Chem 19:1302–1308, 1976.

    Google Scholar 

  5. Driscoll JS: Aziridinylquinone antitumor agents. Chem Abste 87:194–230, 1977.

    Google Scholar 

  6. Savaraj NS, Lu K, Fenn LF, Leavens ME, Stewart D, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis (carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986) J Neuro-Oncol 1: 15–19, 1983.

    Google Scholar 

  7. Bedikian AY, Bodey GP, Burgess MA, Freireich EJ: Phase I study of aziridinylbenzoquinone (NSC 182986). Cancer Clin Trials 4:459–463, 1981.

    Google Scholar 

  8. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958.

    Google Scholar 

  9. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223, 1965.

    Google Scholar 

  10. Levin VA, Hoffman WK, Pischer TL et al: BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62:2071–2076, 1978.

    Google Scholar 

  11. Feun LG, Stewart DJ, Leavens ME et al: A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignan brain tumors. J Neuro-Oncol 1:45–48, 1983.

    Google Scholar 

  12. Aroney RS, Kaplan RS, Saleman M et al: A phase II trial of AZQ (NSC 182986) in patients with recurrent primary or metastatic brain tumors. ASCO (Abstract) 1:24, 1982.

    Google Scholar 

  13. Curt GA, Schilsky R, Kelly J et al: Phase II study of AZQ in malignant high-grade gliomas. ASCO (Abstract) 1:13, 1982.

    Google Scholar 

  14. Hochberg FH, Parker LM, Takvorian T et al: High dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54:455–460, 1981.

    Google Scholar 

  15. Feun LG, Savaraj N, Lu K et al: The pharmacologic fate of 2,5-diaziridinyl-3,6-bis (carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles. J Neuro-Oncol 1:219–224, 1983.

    Google Scholar 

  16. Yung W-KA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42:992–998, 1982.

    Google Scholar 

  17. Schold SC Jr, Friedman HS, Bjornsson TD et al: Treatment of human brain tumors in athymic mice with aziridinylbenzoquinone (AZQ). Proc Am Assoc Can Res 23:176, 1982.

    Google Scholar 

  18. Eagan RT, Creagan ET, Bisel HF et al: Phase II studies of dianhyrogalactitol-based combination chemotherapy for recurrent brain tumors. Oncology 38:4–6, 1981.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Neuro-Oncology, USA

    Lynn G. Feun, Wai-Kwan A. Yung, Milam E. Leavens, Eugenie A. Obbens & William S. Fields

  2. Department of Internal Medicine, Section of Melanoma/Sarcoma, USA

    Robert S. Benjamin

  3. Department of Developmental Therapeutics, University of Texas at Houston, M. D. Anderson Hospital and Tumor Institute, 77030, Houston, Texas

    M. Andrews Burgess, Niramol Savaraj & G. P. Bodey

  4. Ontario, Ottawa

    David J. Stewart

  5. Medical Affairs Department, Medical Oncology Section, King Faisal Specialist Hospital and Research Section, P. O. Box 3354, Riyadh, Saudia Arabia

    Agop Y. Bedikian

Authors
  1. Lynn G. Feun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wai-Kwan A. Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Milam E. Leavens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Andrews Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugenie A. Obbens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Agop Y. Bedikian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Niramol Savaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Robert S. Benjamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. William S. Fields
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. P. Bodey
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by NCI Contract NO1-CM-97277

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feun, L.G., Yung, WK.A., Leavens, M.E. et al. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors. J Neuro-Oncol 2, 13–17 (1984). https://doi.org/10.1007/BF00165153

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00165153

Keywords

Search

Navigation